Aligos Therapeutics, Inc (ALGS)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Lawrence M. Blatt |
| Employees: | 90 |
| Web site: | www.aligos.com |
|
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
(800) 466-6059
| |
| Date | Ratio |
|---|---|
| 2024-08-19 | 1:25 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)
Please log in first to see chart